Blood Res.  2023 Sep;58(3):155-157. 10.5045/br.2023.2023136.

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm

• Kim DH
• Byun JM
• Shin DY
• Kim I
• Yoon SS
• Koh Y

• KMID: 2546319
• DOI: http://doi.org/10.5045/br.2023.2023136

Reference

1. Abdulkarim K, Girodon F, Johansson P, et al. 2009; AML transformation in 56 patients with Ph− MPD in two well defined populations. Eur J Haematol. 82:106–11. DOI: 10.1111/j.1600-0609.2008.01163.x. PMID: 19134023.

2. Heaney ML, Soriano G. 2013; Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy. Curr Hematol Malig Rep. 8:116–22. DOI: 10.1007/s11899-013-0154-5. PMID: 23572311.

3. Abdel-Wahab O, Manshouri T, Patel J, et al. 2010; Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70:447–52. DOI: 10.1158/0008-5472.CAN-09-3783. PMID: 20068184. PMCID: PMC2947340.

4. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. 2010; BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 34:1255–68. DOI: 10.1016/j.leukres.2010.04.016. PMID: 20537386.

5. Baxter EJ, Scott LM, Campbell PJ, et al. 2005; Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–61. DOI: 10.1016/S0140-6736(05)71142-9. PMID: 15781101.

6. Eghtedar A, Verstovsek S, Estrov Z, et al. 2012; Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 119:4614–8. DOI: 10.1182/blood-2011-12-400051. PMID: 22422826. PMCID: PMC4081383.

7. Nangalia J, Green TR. 2014; The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014:287–96. DOI: 10.1182/asheducation-2014.1.287. PMID: 25696868.

8. Beer PA, Delhommeau F, LeCouédic JP, et al. 2010; Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 115:2891–900. DOI: 10.1182/blood-2009-08-236596. PMID: 20008300.

9. Cheson BD, Bennett JM, Kopecky KJ, et al. 2003; Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 21:4642–9. DOI: 10.1200/JCO.2003.04.036. PMID: 14673054.

10. Abaza Y, Kantarjian H, Alwash Y, et al. 2020; Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 95:1288–95. DOI: 10.1002/ajh.25939. PMID: 32681739.

11. Passamonti F, Rumi E, Arcaini L, et al. 2005; Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 104:1032–6. DOI: 10.1002/cncr.21297. PMID: 16047334.

12. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. 2005; Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 105:973–7. DOI: 10.1182/blood-2004-07-2864. PMID: 15388582.

13. Mascarenhas JO, Rampal RK, Kosiorek HE, et al. 2020; Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 4:5246–56. DOI: 10.1182/bloodadvances.2020002119. PMID: 33104796. PMCID: PMC7594401.

14. Rampal R, Ahn J, Abdel-Wahab O, et al. 2014; Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 111:E5401–10. DOI: 10.1073/pnas.1407792111. PMID: 25516983. PMCID: PMC4273376.

15. Bose P, Verstovsek S, Cortes JE, et al. 2020; A phase 1/2 study of Ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 34:2489–92. DOI: 10.1038/s41375-020-0778-0. PMID: 32099037.